Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA

  |  Issue: July 2017, June 2007  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Hirschler B. Heart safety clouds hopes for Amgen, UCB bone drug. Reuters. 2017 May 23.
  2. Amgen Inc. News release: Amgen and UCB announce top-line phase 3 data from active-comparator study of Evenity (romosozumab) in postmenopausal women with osteoporosis. 2017 May 21.
  3. Roche. News release: FDA grants priority review for Roche’s Actemra/RoActemra (tocilizumab) supplemental biologics license application for giant cell arteritis, a form of vasculitis. 2017 Jan 24.
  4. Genentech Inc. News release: FDA approves Genentech’s Actemra (tocilizumab) for giant cell arteritis. 2017 May 22.
  5. Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017 May 9;357:j1909.
  6. U.S. Food and Drug Administration. FDA drug safety communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). 2017 May 16.

Related Articles

    NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin

    NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…